The Effect of ACEi/ARB on Survival Outcome of Patients with Mcrpc Treated with Abiraterone.
Junliang Zhao,Xinyang Cai,Zhenyu Yang,Xingbo Long,Tianyou Zhang,Diwei Zhao,Yuanwei Li,Fangjian Zhou,Jun Wang,Yonghong Li
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.5071
IF: 45.3
2024-01-01
Journal of Clinical Oncology
Abstract:5071 Background: Androgen deprivation therapy (ADT), such as Abiraterone Acetate (AA), has emerged as a standard treatment for metastatic prostate cancer (mPCa). However, long-term ADT treatment may increase the incidence of cardiovascular adverse events, such as hypertension, which are a common cause of death in patients receiving ADT. Therefore, it is crucial to select appropriate antihypertensive drugs that effectively manage blood pressure and improve overall survival (OS) in these patients. Methods: This study conducted a secondary analysis of the COU-AA-301 and COU-AA-302 trials, which were multicenter double-blind randomized controlled trials (RCTs) to evaluate the efficacy of AA in combination with prednisone and ADT compared to prednisone plus ADT alone in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients were retrospectively assessed and stratified based on the concurrent medication including angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) or not. OS and progression-free survival (PFS) were assessed using the Kaplan-Meier method and log-rank test. Multivariable Cox regression analysis was performed to determine the independent correlation of ACEi/ARBs with OS and PFS. Statistical significance was defined as P<0.05. Results: In COU-AA-301, the use of ACEi/ARB medications showed a significant association with improved OS (16.4 vs. 14.2 months, p<0.001) and PFS (3.1 vs. 2.9 months, p=0.002) in AA arm. After adjusting for baseline factors, ACEi/ARB medications were still found to reduce the risk of death (HR 0.72, 95% CI 0.56-0.91) and disease progression (HR 0.81, 95% CI 0.69-0.96). Similarly, in COU-AA-302, ACEi/ARB medications were associated with prolonged OS (37.4 vs. 31.9 months, p=0.003) and PFS (20.3 vs. 14.7 months, p=0.002) in AA arm. By adjusting for baseline factors, ACEi/ARB medications remained significantly associated with lower risk of death (HR 0.70, 95% CI 0.56-0.88) and disease progression (HR 0.70, 95% CI 0.55-0.88). In the placebo group, ACEi/ARB medications demonstrated improved OS only in COU-AA-301 (13.7 vs. 10.6 months, p=0.021). However, this trend did not reach statistical significance after adjusting for baseline factors (HR 0.76, 95% CI 0.55-1.03). Furthermore, the use of ACEi/ARB medications did not confer any PFS benefits in COU-AA-301 and failed to show both PFS and OS benefits in COU-AA-302. Conclusions: The use of ACEi/ARB medications has shown promise in improving OS and PFS in mCRPC patients treated with AAP. However, it is important to acknowledge the inherent limitations of post-hoc analysis, and therefore, further validation through prospective clinical trials is warranted.